AZSTARYS Drug Patent Profile

When do Azstarys patents expire, and when can generic versions of Azstarys launch?

Azstarys is a drug marketed by Commave Therap and is included in one NDA. There are six patents protecting this drug.

This drug has eighty-seven patent family members in thirty-one countries.

The generic ingredient in AZSTARYS is dexmethylphenidate hydrochloride; serdexmethylphenidate chloride. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dexmethylphenidate hydrochloride; serdexmethylphenidate chloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Azstarys

Azstarys was eligible for patent challenges on May 7, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 9, 2037. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for AZSTARYS

International Patents:	87
US Patents:	6
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for AZSTARYS

AZSTARYS is protected by six US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Commave Therap	AZSTARYS	dexmethylphenidate hydrochloride; serdexmethylphenidate chloride	CAPSULE;ORAL	212994-001	May 7, 2021		RX	Yes	No
Commave Therap	AZSTARYS	dexmethylphenidate hydrochloride; serdexmethylphenidate chloride	CAPSULE;ORAL	212994-003	May 7, 2021		RX	Yes	Yes			Y
Commave Therap	AZSTARYS	dexmethylphenidate hydrochloride; serdexmethylphenidate chloride	CAPSULE;ORAL	212994-001	May 7, 2021		RX	Yes	No
Commave Therap	AZSTARYS	dexmethylphenidate hydrochloride; serdexmethylphenidate chloride	CAPSULE;ORAL	212994-001	May 7, 2021		RX	Yes	No			Y

International Patents for AZSTARYS

When does loss-of-exclusivity occur for AZSTARYS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Denmark

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Poland

Portugal

San Marino

Serbia

Slovenia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AZSTARYS around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	201308766	METHYLPHENIDATE-PRODRUGS,PROCESSES OF MAKING AND USING THE SAME
Japan	6505822
Brazil	112019011640
Colombia	6900135

Investment Scenario, Market Dynamics, and Financial Trajectory for AZSTARYS

Last updated: February 3, 2026

Executive Summary

AZSTARYS (serdexmethylphenidate and dexmethylphenidate) is a prescription drug developed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adults. Launched by Sun Pharmacare, Inc., and marketed by Supernus Pharmaceuticals, Inc., AZSTARYS represents a novel oral neurostimulant with a unique pharmacokinetic profile. This report assesses the market potential, competitive landscape, regulatory environment, and financial projections associated with AZSTARYS, providing insights for investors and stakeholders.

---

What is the Investment Outlook for AZSTARYS?

Market Adoption Potential

• Market size: Estimated at approximately $12.6 billion in 2022 in the U.S. alone, projected to grow at a CAGR of 6-8% to reach $17 billion by 2027 (1).
• Target demographic: Children aged 6-12 and adults diagnosed with ADHD.
• Market penetration: As of 2023, AZSTARYS's approved indications position it as a potential alternative to established treatments like Adderall, Vyvanse, and Concerta.

Competitive Positioning

• Unique drug profile: Combines immediate and gradual release mechanisms for sustained efficacy.
• Regulatory status: Approved by FDA in June 2021 with a priority review process due to unmet needs.
• Market penetration challenges: Competition from long-established drugs with extensive prescriber familiarity and insurance coverage.

Revenue Projections

• Year 1 (2022-2023): Estimated revenue of $50–$100 million.
• Year 3 (2024-2025): Possible escalation to $300–$500 million with increased market acceptance.
• Long-term (2025+): Potential to reach $1 billion with expanded indications and geographic expansion.

Investment Risks

Risk Factor	Description	Mitigation Strategy
Market Penetration	Slow uptake due to prescriber preference	Education, clinical data dissemination
Competitive Dynamics	Established brands with entrenched market share	Differentiation via unique profile
Regulatory Changes	Potential restrictions or new label requirements	Active engagement with regulators
Reimbursement Landscape	Payer coverage challenges	Negotiation and formulary positioning

---

Market Dynamics: Drivers, Trends, & Challenges

Key Market Drivers

• Rising prevalence of ADHD globally, reported at 7.2% in children and 3.4% in adults (2).
• Increasing diagnosis rates, heightened awareness, and affordable therapy options.
• Demand for medications with reduced abuse potential; AZSTARYS's formulation offers abuse deterrent properties.

Current Trends in ADHD Pharmacotherapy

Trend	Impact on AZSTARYS
Shift toward non-stimulant options	Positions AZSTARYS favorably with its unique delivery system
Growth in adult ADHD treatment	Expanding market segment for AZSTARYS
Focus on long-acting formulations	AZSTARYS's sustained release profile aligns with this trend

Challenges in Market Dynamics

Challenge	Description	Possible Mitigation
Brand loyalty to existing drugs	Prescriber and patient familiarity with established brands	Clinical superiority demonstration
Insurance coverage variability	Reimbursement coverage affecting patient access	Payer negotiations
Regulatory hurdles	Ensuring label expansion for new indications or populations	Continuous regulatory engagement

---

Financial Trajectory and Investment Metrics

Revenue Breakdown (Estimated)

Year	Estimated Revenue (USD millions)	Notes
2022	$50–$100	Market entry, initial uptake
2023	$150–$250	Increased prescriber adoption, expanded access
2024	$300–$500	Broader insurance coverage, geographic expansion
2025	$700–$1,000	Growing market share, new indications

Cost Structure & Margin Expectations

Cost Category	% of Revenue	Remarks
Manufacturing	15–20%	Economies of scale expected
Marketing & Sales	20–25%	Significant investment needed for market capture
R&D	5–10%	Post-approval development, new indications
General & Administrative	10–15%	Infrastructure, compliance costs

Profitability Outlook

• Break-even point: Estimated within 18–24 months post-launch, contingent on sales volume and reimbursement.
• Operating margins: Expected to improve from 10% in Year 1 to 25–30% by Year 3 with increased operational efficiencies.

Valuation Considerations

• Market share assumptions: 10–20% share in the ADHD drug market within 3 years.
• Pricing strategy: Average wholesale price (AWP) around $300–$400 per month per patient.
• ROI projections: Cumulative revenues in excess of $3 billion over 5 years under favorable adoption scenarios.

---

Comparative Analysis with Similar Drugs

Drug	Release Type	Indications	Starting Price (monthly)	Market Share (est.)	Key Differentiator
AZSTARYS	Ongoing, sustained	ADHD	$350	10-15% (by Year 3)	Combined immediate and delayed release
Adderall XR	Long-acting	ADHD, Narcolepsy	$300	30%	Established market leader
Vyvanse	Long-acting	ADHD, BED	$350	20%	Abuse-deterrent formulation

Note: Advanced pharmacokinetic profile positions AZSTARYS favorably for the long-term.

---

Regulatory & Policy Environment

FDA Approvals & Considerations

• Approved June 2021 under Priority Review due to high unmet needs (3, 2021).
• Post-marketing studies may be required to assess long-term safety and efficacy.

Reimbursement & Insurance

• Coverage likely to evolve with formulary assessments based on efficacy, safety, and cost-effectiveness.
• Payer negotiations critical; early engagement essential for market penetration.

Legislative Impact

• Potential policy shifts favoring access to newer formulations and pediatric ADHD treatments.
• Regulatory pathways for new indications remain critical for growth.

---

Comparison with Market Leaders

Attribute	AZSTARYS	Adderall XR	Vyvanse	Concerta
Formulation Type	Hybrid immediate/ER	ER	ER	ER
Abuse Potential	Lower	Moderate	Lower	Moderate
Market Launch Year	2021	1996	2007	2000
Pricing	~$350/month	~$300/month	~$350/month	~$250/month
Market Penetration	Growing	Established	Growing	Established

Key Success Factors for Investment

• Clinical Evidence: Demonstrating superior efficacy or safety profiles.
• Market Education: Increasing clinician familiarity with AZSTARYS's benefits.
• Reimbursement Strategy: Navigating payer landscape efficiently.
• Expansion Potential: Sponsoring indications beyond pediatric ADHD and geographic markets.

---

Key Takeaways

• Market opportunity: Significant growth driven by rising ADHD prevalence and demand for innovative treatments.
• Competitive positioning: Differentiated by pharmacokinetics, abuse potential mitigation, and safety profile.
• Financial prospects: Revenue forecast indicates positive trajectory within 2-3 years, assuming successful market adoption.
• Risks: Market penetration hurdles, competition, regulatory and reimbursement challenges.
• Strategic focus: Investment should favor firms with strong clinical data, robust reimbursement strategies, and proactive regulatory engagement.

---

FAQs

1. What are the primary advantages of AZSTARYS over traditional ADHD medications?

AZSTARYS offers a unique hybrid-release profile that provides both immediate and sustained symptom control with a lower abuse potential than some stimulant counterparts, potentially improving safety and adherence.

2. How does regulatory approval impact AZSTARYS's market prospects?

FDA approval, especially under a priority review process, fast-tracks market entry but necessitates ongoing post-marketing commitments to demonstrate long-term safety, influencing future reimbursement and formulary positioning.

3. What is the potential for AZSTARYS in adult ADHD?

While initially approved for children aged 6 and above, expanding indications to include adults is feasible pending clinical studies, opening substantial revenue possibilities, given the increasing prevalence of adult ADHD.

4. How does reimbursement landscape influence AZSTARYS's market success?

Effective reimbursement strategies are critical; favorable insurance coverage drives patient access, impacts sales volume, and ultimately determines revenue growth.

5. What are the key challenges for investors in the AZSTARYS market?

Challenges include aggressive competition, prescriber adoption rates, payer negotiations, regulatory hurdles for new indications, and ensuring consistent supply chain and manufacturing quality.

---

References

1. Mordor Intelligence. (2022). ADHD Drugs Market — Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027.
2. Thomas, R.E., et al. (2018). Prevalence of ADHD: A systematic review. JAMA Pediatrics.
3. FDA. (2021). FDA Approves New Drug Treatment for ADHD. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-adhd.

Note: Data points are estimates and projections based on current market analytics, regulatory filings, and industry reports.

---

End of Report